Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
Sponsor: BioXcel Therapeutics Inc
Summary
This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years and older) males and females with acute agitation associated with dementia. Evaluation of 3 doses are planned.
Official title: A Phase Ib/II, Multicenter, Randomized, Double Blind, Placebo Controlled, Ascending Dose Finding, Efficacy, Pharmacokinetic and Safety Study of BXCL501 In Agitation Associated With Dementia
Key Details
Gender
All
Age Range
65 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2019-12-27
Completion Date
2022-01-24
Last Updated
2026-06-03
Healthy Volunteers
No
Conditions
Interventions
Sublingual film containing Dexmedetomidine
Sublingual film containing Dexmedetomidine
Sublingual Placebo Film
Sublingual placebo film that matches BXCL501
Locations (5)
BioXcel Clinical Research Site
Homestead, Florida, United States
BioXcel Clinical Research Site
Miami Lakes, Florida, United States
BioXcel Clinical Research Site
Springfield, Massachusetts, United States
BioXcel Clinical Research Site
Caro, Michigan, United States
BioXcel Clinical Research Site
Toms River, New Jersey, United States